Genitourinary Cancers Symposium Annual Meeting Coverage

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

Pembrolizumab Shows Promise for BCG-Unresponsive Bladder Cancer

Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Radical Cystectomy Superior to Trimodal Therapy for Muscle-Invasive Bladder Cancer

Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma

Compared with sorafenib, tivozanib was associated with improved progression-free survival and objective response rate, researchers reported.

Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma

Radiation, Chemotherapy Not Beneficial in Localized Upper Tract Urothelial Carcinoma

In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC

About 25% of patients with previously untreated advanced non-clear cell renal cell carcinoma had an objective response to pembrolizumab.

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma

Avelumab-axitinib regimen offers better progression-free survival and responses than sunitinib for patients with previously untreated advanced RCC, regardless of risk group or PD-L1 status.

Early Tumor Shrinkage With Cabozantinib Improves Survival in RCC

Early Tumor Shrinkage With Cabozantinib Improves Survival in RCC

New analysis shows that early tumor shrinkage with cabozantinib is associated with longer survival compared with everolimus.

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed

Patients with treatment-naive, intermediate- and poor-risk advanced RCC continue to have superior overall survival with the dual ICI regimen compared with sunitinib alone.

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma

As first-line therapy for locally advanced or metastatic renal cell carcinoma, pembrolizumab plus axitinib offers longer overall and progression-free survival compared with sunitinib.

Obesity Linked With Improved Survival in mCRPC

Obesity Linked With Improved Survival in mCRPC

Obese men treated with docetaxel for metastatic castration-resistant prostate cancer have longer cancer-specific and overall survival, a study found.

Radium-223 Use in mCRPC Differs By Race

Radium-223 Use in mCRPC Differs By Race

Study shows that black men with metastatic castration-resistant prostate cancer may be experiencing a delay in receiving radium-223 compared with nonblack men.

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Brachytherapy for Favorable-Risk Prostate Cancer Continues to Decline

Among men receiving radiation therapy for prostate cancer, the proportion of those receiving brachytherapy dropped from 59.3% to 34.7% from 2004 to 2014, a study found.

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

Abiraterone, Prednisone With Androgen Deprivation Therapy Show Durable Efficacy in Metastatic Castration-Naive Prostate Cancer

At a median follow-up of nearly 52 months, the treatment regimen deceased mortality risk among men with high-risk metastatic castration-naive prostate cancer by 30%.

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

Metastatic Prostate Cancer Responds to Novel Radiation Therapy

By targeting prostate-specific membrane antigen, a molecule radiolabeled with lutetium-177 is expected to deliver high doses of beta radiation to distant metastases.

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Trial Update for Apalutamide in Nonmetastatic Castration-Resistant Prostate Cancer

After an additional 1 year of follow-up, apalutamide plus ADT continued to show a significant decrease in the risk of progression to metastasis or death.

Renal and Urology News Articles

Sign Up for Free e-newsletters